Cynthia Carlsson, MD, MS, spoke to multiple media outlets after the U.S. Food and Drug Administration’s (FDA) full approval of lecanemab was announced. She emphasized the treatment will only be approved for people who are diagnosed with mild cognitive impairment (MCI) or mild dementia and also meet other limited criteria.
On July 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb), a therapy for Alzheimer’s disease shown to slow the cognitive decline associated with the disease.
The renewal grant will enable continued in-depth study into biological indicators of Alzheimer’s disease, expansion of the project to identify other causes of cognitive decline, and enhance the diversity of the cohort through recruitment of people from communities historically underrepresented in research.
Called the Equity Prioritization Plan, this project will utilize the Area Deprivation Index (ADI) – a tool developed by Dr. Amy Kind’s research team at the Center for Health Disparities Research (CDHR) - as the cornerstone of its metric to identify neighborhoods in greatest need of lead service line replacement.
Barb Bendlin, PhD, was the keynote speaker at the Alzheimer’s Association Wisconsin Chapter’s 37th Annual Wisconsin State Conference, held May 21-22, 2023, at the Wilderness Resort in Wisconsin Dells, WI.
A group of researchers, nurses, social workers, and students at the UW School of Medicine and Public Health are working to help older adults develop the knowledge and tools needed to protect their brain health and the know-how to connect with resources and extra support when needed.
Ozioma Okonkwo, PhD, was quoted in a recent article in the Wisconsin State Journal about the SuperAging study at the Wisconsin Alzheimer’s Disease Research Center (ADRC).
Though there is extensive research being done on ways to improve one’s longevity, exercise remains one of the most powerful things a person can do to improve their health and protect against diseases of aging.